PMC:7199903 / 0-418 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":72,"end":79},"obj":"Body_part"},{"id":"T2","span":{"begin":210,"end":217},"obj":"Body_part"},{"id":"T3","span":{"begin":358,"end":363},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":37,"end":45},"obj":"Disease"},{"id":"T2","span":{"begin":55,"end":63},"obj":"Disease"},{"id":"T3","span":{"begin":116,"end":163},"obj":"Disease"},{"id":"T4","span":{"begin":116,"end":149},"obj":"Disease"},{"id":"T5","span":{"begin":165,"end":173},"obj":"Disease"},{"id":"T6","span":{"begin":233,"end":242},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":177,"end":187},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T2","span":{"begin":280,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T3","span":{"begin":284,"end":286},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T4","span":{"begin":358,"end":363},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T5","span":{"begin":368,"end":373},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":72,"end":79},"obj":"Chemical"},{"id":"T2","span":{"begin":210,"end":217},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T1","span":{"begin":0,"end":4},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T2","span":{"begin":233,"end":242},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T3","span":{"begin":301,"end":306},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T4","span":{"begin":318,"end":323},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T5","span":{"begin":358,"end":363},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T6","span":{"begin":368,"end":373},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T7","span":{"begin":378,"end":384},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T14","span":{"begin":112,"end":115},"obj":"IN"},{"id":"T15","span":{"begin":116,"end":122},"obj":"JJ"},{"id":"T16","span":{"begin":123,"end":128},"obj":"JJ"},{"id":"T17","span":{"begin":129,"end":140},"obj":"JJ"},{"id":"T18","span":{"begin":141,"end":149},"obj":"NN"},{"id":"T19","span":{"begin":150,"end":161},"obj":"NN"},{"id":"T20","span":{"begin":162,"end":163},"obj":"CD"},{"id":"T21","span":{"begin":164,"end":165},"obj":"-LRB-"},{"id":"T0","span":{"begin":0,"end":13},"obj":"JJ"},{"id":"T1","span":{"begin":14,"end":20},"obj":"NN"},{"id":"T2","span":{"begin":21,"end":29},"obj":"NN"},{"id":"T3","span":{"begin":30,"end":32},"obj":"IN"},{"id":"T4","span":{"begin":33,"end":36},"obj":"DT"},{"id":"T5","span":{"begin":37,"end":47},"obj":"NN"},{"id":"T6","span":{"begin":48,"end":53},"obj":"NN"},{"id":"T7","span":{"begin":55,"end":65},"obj":"NN"},{"id":"T8","span":{"begin":66,"end":71},"obj":"NN"},{"id":"T9","span":{"begin":72,"end":79},"obj":"NN"},{"id":"T10","span":{"begin":79,"end":80},"obj":"-COMMA-"},{"id":"T11","span":{"begin":81,"end":91},"obj":"VBD"},{"id":"T12","span":{"begin":92,"end":99},"obj":"NN"},{"id":"T13","span":{"begin":100,"end":111},"obj":"NN"},{"id":"T22","span":{"begin":165,"end":175},"obj":"NN"},{"id":"T23","span":{"begin":175,"end":176},"obj":"-RRB-"},{"id":"T24","span":{"begin":177,"end":179},"obj":"VBZ"},{"id":"T25","span":{"begin":180,"end":187},"obj":"VBN"},{"id":"T26","span":{"begin":188,"end":190},"obj":"IN"},{"id":"T27","span":{"begin":191,"end":194},"obj":"DT"},{"id":"T28","span":{"begin":195,"end":203},"obj":"JJ"},{"id":"T29","span":{"begin":204,"end":209},"obj":"NN"},{"id":"T30","span":{"begin":210,"end":217},"obj":"NN"},{"id":"T31","span":{"begin":218,"end":222},"obj":"WDT"},{"id":"T32","span":{"begin":223,"end":232},"obj":"VBZ"},{"id":"T33","span":{"begin":233,"end":242},"obj":"NN"},{"id":"T34","span":{"begin":244,"end":248},"obj":"DT"},{"id":"T35","span":{"begin":249,"end":257},"obj":"NN"},{"id":"T36","span":{"begin":258,"end":260},"obj":"IN"},{"id":"T37","span":{"begin":261,"end":264},"obj":"DT"},{"id":"T38","span":{"begin":265,"end":273},"obj":"JJ"},{"id":"T39","span":{"begin":274,"end":279},"obj":"NN"},{"id":"T40","span":{"begin":280,"end":283},"obj":"VBZ"},{"id":"T41","span":{"begin":284,"end":286},"obj":"CD"},{"id":"T42","span":{"begin":287,"end":300},"obj":"NN"},{"id":"T43","span":{"begin":301,"end":306},"obj":"NNS"},{"id":"T44","span":{"begin":308,"end":311},"obj":"WRB"},{"id":"T45","span":{"begin":312,"end":317},"obj":"DT"},{"id":"T46","span":{"begin":318,"end":323},"obj":"NNS"},{"id":"T47","span":{"begin":324,"end":327},"obj":"VBP"},{"id":"T48","span":{"begin":328,"end":340},"obj":"VBN"},{"id":"T49","span":{"begin":341,"end":344},"obj":"MD"},{"id":"T50","span":{"begin":345,"end":351},"obj":"VB"},{"id":"T51","span":{"begin":352,"end":357},"obj":"WDT"},{"id":"T52","span":{"begin":358,"end":363},"obj":"NNS"},{"id":"T53","span":{"begin":364,"end":367},"obj":"DT"},{"id":"T54","span":{"begin":368,"end":373},"obj":"NN"},{"id":"T55","span":{"begin":374,"end":377},"obj":"MD"},{"id":"T56","span":{"begin":378,"end":384},"obj":"VB"},{"id":"T57","span":{"begin":385,"end":388},"obj":"CC"},{"id":"T58","span":{"begin":389,"end":394},"obj":"MD"},{"id":"T59","span":{"begin":395,"end":401},"obj":"VB"},{"id":"T60","span":{"begin":402,"end":406},"obj":"DT"},{"id":"T61","span":{"begin":407,"end":415},"obj":"NNS"}],"relations":[{"id":"R0","pred":"arg1Of","subj":"T2","obj":"T0"},{"id":"R1","pred":"arg1Of","subj":"T2","obj":"T1"},{"id":"R2","pred":"arg1Of","subj":"T2","obj":"T3"},{"id":"R3","pred":"arg2Of","subj":"T6","obj":"T3"},{"id":"R4","pred":"arg1Of","subj":"T6","obj":"T4"},{"id":"R5","pred":"arg1Of","subj":"T6","obj":"T5"},{"id":"R6","pred":"arg1Of","subj":"T9","obj":"T7"},{"id":"R7","pred":"arg1Of","subj":"T9","obj":"T8"},{"id":"R21","pred":"arg1Of","subj":"T13","obj":"T24"},{"id":"R22","pred":"arg2Of","subj":"T25","obj":"T24"},{"id":"R23","pred":"arg2Of","subj":"T13","obj":"T25"},{"id":"R24","pred":"arg1Of","subj":"T25","obj":"T26"},{"id":"R25","pred":"arg2Of","subj":"T30","obj":"T26"},{"id":"R26","pred":"arg1Of","subj":"T30","obj":"T27"},{"id":"R27","pred":"arg1Of","subj":"T30","obj":"T28"},{"id":"R28","pred":"arg1Of","subj":"T30","obj":"T29"},{"id":"R29","pred":"arg1Of","subj":"T30","obj":"T31"},{"id":"R8","pred":"arg1Of","subj":"T11","obj":"T10"},{"id":"R9","pred":"arg1Of","subj":"T9","obj":"T11"},{"id":"R10","pred":"arg1Of","subj":"T13","obj":"T12"},{"id":"R11","pred":"arg1Of","subj":"T13","obj":"T14"},{"id":"R12","pred":"arg2Of","subj":"T19","obj":"T14"},{"id":"R13","pred":"arg1Of","subj":"T19","obj":"T15"},{"id":"R14","pred":"arg1Of","subj":"T19","obj":"T16"},{"id":"R15","pred":"arg1Of","subj":"T19","obj":"T17"},{"id":"R16","pred":"arg1Of","subj":"T19","obj":"T18"},{"id":"R17","pred":"arg1Of","subj":"T19","obj":"T20"},{"id":"R18","pred":"arg1Of","subj":"T19","obj":"T21"},{"id":"R19","pred":"arg2Of","subj":"T22","obj":"T21"},{"id":"R20","pred":"arg3Of","subj":"T23","obj":"T21"},{"id":"R30","pred":"arg1Of","subj":"T30","obj":"T32"},{"id":"R31","pred":"arg2Of","subj":"T33","obj":"T32"},{"id":"R32","pred":"arg1Of","subj":"T35","obj":"T34"},{"id":"R33","pred":"arg1Of","subj":"T35","obj":"T36"},{"id":"R34","pred":"arg2Of","subj":"T39","obj":"T36"},{"id":"R35","pred":"arg1Of","subj":"T39","obj":"T37"},{"id":"R36","pred":"arg1Of","subj":"T39","obj":"T38"},{"id":"R37","pred":"arg1Of","subj":"T35","obj":"T40"},{"id":"R38","pred":"arg2Of","subj":"T43","obj":"T40"},{"id":"R39","pred":"arg1Of","subj":"T43","obj":"T41"},{"id":"R40","pred":"arg1Of","subj":"T43","obj":"T42"},{"id":"R41","pred":"arg1Of","subj":"T48","obj":"T44"},{"id":"R42","pred":"arg1Of","subj":"T46","obj":"T45"},{"id":"R43","pred":"arg1Of","subj":"T46","obj":"T47"},{"id":"R44","pred":"arg2Of","subj":"T48","obj":"T47"},{"id":"R45","pred":"arg2Of","subj":"T46","obj":"T48"},{"id":"R46","pred":"arg1Of","subj":"T44","obj":"T49"},{"id":"R47","pred":"arg2Of","subj":"T50","obj":"T49"},{"id":"R48","pred":"arg1Of","subj":"T44","obj":"T50"},{"id":"R49","pred":"arg2Of","subj":"T51","obj":"T50"},{"id":"R50","pred":"arg1Of","subj":"T52","obj":"T51"},{"id":"R51","pred":"arg1Of","subj":"T54","obj":"T53"},{"id":"R52","pred":"arg1Of","subj":"T54","obj":"T55"},{"id":"R53","pred":"arg2Of","subj":"T56","obj":"T55"},{"id":"R54","pred":"arg1Of","subj":"T54","obj":"T56"},{"id":"R55","pred":"arg2Of","subj":"T52","obj":"T56"},{"id":"R56","pred":"arg1Of","subj":"T50","obj":"T57"},{"id":"R57","pred":"arg2Of","subj":"T59","obj":"T57"},{"id":"R58","pred":"arg1Of","subj":"T44","obj":"T58"},{"id":"R59","pred":"arg2Of","subj":"T59","obj":"T58"},{"id":"R60","pred":"arg1Of","subj":"T44","obj":"T59"},{"id":"R61","pred":"arg2Of","subj":"T61","obj":"T59"},{"id":"R62","pred":"arg1Of","subj":"T61","obj":"T60"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T1","span":{"begin":72,"end":79},"obj":"Body_part"},{"id":"T2","span":{"begin":210,"end":217},"obj":"Body_part"},{"id":"T3","span":{"begin":358,"end":363},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T1","span":{"begin":72,"end":79},"obj":"Chemical"},{"id":"T2","span":{"begin":210,"end":217},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T1","span":{"begin":37,"end":47},"obj":"Species"},{"id":"T2","span":{"begin":55,"end":65},"obj":"Species"},{"id":"T3","span":{"begin":116,"end":163},"obj":"Species"},{"id":"T4","span":{"begin":165,"end":175},"obj":"Species"}],"attributes":[{"id":"A1","pred":"ncbi_taxonomy_id","subj":"T1","obj":"NCBItxid:2697049"},{"id":"A2","pred":"ncbi_taxonomy_id","subj":"T2","obj":"NCBItxid:2697049"},{"id":"A3","pred":"ncbi_taxonomy_id","subj":"T3","obj":"NCBItxid:2697049"},{"id":"A4","pred":"ncbi_taxonomy_id","subj":"T4","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":53},"obj":"Sentence"},{"id":"T2","span":{"begin":55,"end":91},"obj":"Sentence"},{"id":"T3","span":{"begin":92,"end":243},"obj":"Sentence"},{"id":"T4","span":{"begin":244,"end":307},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":37,"end":47},"obj":"Disease"},{"id":"T2","span":{"begin":55,"end":65},"obj":"Disease"},{"id":"T3","span":{"begin":116,"end":163},"obj":"Disease"},{"id":"T4","span":{"begin":165,"end":175},"obj":"Disease"},{"id":"T5","span":{"begin":233,"end":242},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"17","span":{"begin":204,"end":209},"obj":"Gene"},{"id":"19","span":{"begin":116,"end":163},"obj":"Species"},{"id":"2","span":{"begin":37,"end":47},"obj":"Species"},{"id":"20","span":{"begin":165,"end":175},"obj":"Species"},{"id":"21","span":{"begin":274,"end":279},"obj":"Gene"},{"id":"25","span":{"begin":233,"end":242},"obj":"Disease"},{"id":"6","span":{"begin":66,"end":71},"obj":"Gene"},{"id":"7","span":{"begin":55,"end":65},"obj":"Species"},{"id":"T2","span":{"begin":14,"end":20},"obj":"Chemical"}],"attributes":[{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"Tax:2697049"},{"id":"A17","pred":"pubann:denotes","subj":"17","obj":"Gene:43740568"},{"id":"A25","pred":"pubann:denotes","subj":"25","obj":"MESH:D007239"},{"id":"A19","pred":"pubann:denotes","subj":"19","obj":"Tax:2697049"},{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:43740568"},{"id":"A546","pred":"pubann:denotes","subj":"T2","obj":"MESH:D011134"},{"id":"A7","pred":"pubann:denotes","subj":"7","obj":"Tax:2697049"},{"id":"A6","pred":"pubann:denotes","subj":"6","obj":"Gene:43740568"},{"id":"A2","pred":"pubann:denotes","subj":"2","obj":"Tax:2697049"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1","span":{"begin":66,"end":79},"obj":"Protein"},{"id":"T2","span":{"begin":204,"end":217},"obj":"Protein"}],"attributes":[{"id":"A1","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P31340"},{"id":"A2","pred":"uniprot_id","subj":"T2","obj":"https://www.uniprot.org/uniprot/P31340"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":287,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":287,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":287,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":53},"obj":"Sentence"},{"id":"T2","span":{"begin":55,"end":91},"obj":"Sentence"},{"id":"T3","span":{"begin":92,"end":243},"obj":"Sentence"},{"id":"T4","span":{"begin":244,"end":307},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":37,"end":47},"obj":"Species"},{"id":"3","span":{"begin":14,"end":20},"obj":"Chemical"},{"id":"6","span":{"begin":66,"end":71},"obj":"Gene"},{"id":"7","span":{"begin":55,"end":65},"obj":"Species"},{"id":"17","span":{"begin":204,"end":209},"obj":"Gene"},{"id":"19","span":{"begin":116,"end":163},"obj":"Species"},{"id":"20","span":{"begin":165,"end":175},"obj":"Species"},{"id":"21","span":{"begin":274,"end":279},"obj":"Gene"},{"id":"25","span":{"begin":233,"end":242},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"Tax:2697049"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:D011134"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"Gene:43740568"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"Tax:2697049"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Gene:43740568"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:2697049"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Tax:2697049"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:43740568"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Site-specific glycan analysis of the SARS-CoV-2 spike\n\nSARS-CoV-2 spike protein, elaborated\nVaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes fr"}